None listed
Conditions
Brief summary
This is a randomized, triple-blind (subjects, Investigators, and Sponsor blinded), placebo-controlled Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) study to evaluate the safety and tolerability of NVG-291 administered by subcutaneous injection daily in healthy participants. The trial is split into three parts, starting with Part 1 (SAD) and then Parts 2 and 3 (MAD). In Part 1 (SAD), participants receive 1 dose on 1 day only and in Parts 2 and 3 (MAD), participants receive 1 dose every day for 14 days.
Interventions
NVG-291 is a drug injected under the skin (subcutaneous). The trial is split into three parts, starting with Part 1 (SAD), then Part 2 (MAD - post-menopausal Females), and finally Part 3 (MAD - males and premenopausal females). In Part 1 (SAD), participants received 1 dose on 1 day only. Doses began with 0.032 mg/kg (Cohort 1) and increased until 0.864 mg/kg (Cohort 6). Each cohort began after a safety review committee reviewed the data from the previous cohort. An additional cohort was enrolled
NVG-291 is a drug injected under the skin (subcutaneous). The trial is split into three parts, starting with Part 1 (SAD), then Part 2 (MAD - post-menopausal Females), and finally Part 3 (MAD - males and premenopausal females). In Part 1 (SAD), participants received 1 dose on 1 day only. Doses began with 0.032 mg/kg (Cohort 1) and increased until 0.864 mg/kg (Cohort 6). Each cohort began after a safety review committee reviewed the data from the previous cohort. An additional cohort was enrolled at the end of Part 1, to be dosed at 0.864 mg/kg, to assess CSF drug levels. In Part 2 (MAD), postmenopausal female participants received 1 dose daily for for 14 consecutive days. The starting dose for Part 2 was 0.384 mg/kg (2 dose levels lower than the maximum dose achieved during Part 1). There were 3 cohorts in Part 2. The maximum daily dose in Part 2 did not exceed the maximum daily dose tolerated in Part 1. In Part 3 (MAD), male and pre-menopausal female participants will received 0.547 mg/kg daily for for 14 consecutive days. All study parts will be monitored by a qualified CRA to assure study procedures and dose administrations are performed as per protocol.
Sponsors
NervGen Pharma Corp.
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
1. Healthy subjects between 18 and 65 years old. 2. BMI between 18 and 33 kg/m2, inclusive, and a total body weight > 50 kg. 3. All laboratory values must be within normal limits or any abnormalities deemed not clinically significant. 4. All subjects must be willing to abstain from sexual intercourse or to use adequate contraception during the study and for an additional 120 days after the follow-up visit. 5. Subjects must not donate ova or sperm during the study and for an additional 120 days after the follow-up visit 6. Subjects must be willing and able to comply with scheduled visits, all sample collections, and other trial procedures. 7. Subjects must provide written informed consent.
Exclusion criteria
1. For premenopausal female subjects: Irregular menstrual cycles; Amenorrhea; or Abnormal vaginal bleeding 2. A history (within the past year) or presence of a clinically significant infectious disease or hepatic, renal, gastrointestinal, cardiovascular, endocrine, respiratory, immunologic, hematologic, dermatologic, neurologic, or psychiatric abnormality. 3. Blood pressure > 160/95 at screening or on Day -1. 4. Any active or uncontrolled infections or other medical condition or circumstance that could interfere with the subject’s participation in the study. 5. History of allergic reaction to mannitol. 6. Presence of a tattoo, piercing, scar, or other dermatologic abnormality at the injection site (abdomen), that might interfere with the ability to assess injection site reactions 7. a significant history of atopic dermatitis as an adult, or history of severe allergic reaction to injections. 8. INR > 1.4 or PTT > 50 or platelets <50x10^3/µL at screening or on Day -1. 9. History of regular alcohol consumption exceeding 10 units/week (1 unit = 83 mL of 12% wine) within 6 months of screening. 10. Test positive for use of drugs or alcohol at screening. 11. Positive hepatitis B, hepatitis C, or HIV test at screening. 12. Blood or plasma donation within 1 week prior to Day -1. 13. Receipt of an investigational drug within 30 days or five half-lives of the drug (whichever is longer) prior to Day -1. 14. Prior participation in this trial. 15. Female subjects who are breastfeeding or who have a positive pregnancy test at screening or Day -1. 16. History of any condition that might impair the subject’s ability to understand or to comply with the requirements of the study or to provide informed consent. 17. Receipt of a COVID-19 vaccination within 3 weeks prior to Day -1 18. Subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior or endorsing items 4 or 5 on the Columbia-Suicide Severity Rating Scale at screening
Outcome results
None listed